Worldwide Clinical Trials

Guide

Precision Medicine in Hematology-Oncology: Effectively Tailoring Treatments Based on Genetic & Molecular Profiling

Authors

Simran Padam, MD, APMMC
Executive Director, Therapeutic Strategy Lead, Oncology

Matt Cooper, PhD
Executive Director, Therapeutic Strategy Lead, Oncology

Jim Eamma, MSc
Executive Director, Therapeutic Strategy Lead, Oncology

Index

Precision medicine is reshaping the treatment landscape of hematology-oncology, transitioning from traditional, one-size-fits-all approaches to targeted, personalized treatments. Hematologic cancers, in particular, benefit from precision medicine practices due to their extensive genetic and molecular diversity. Utilizing these tailored approaches in clinical trials, CROs can help improve patient selection, treatment efficacy, monitoring strategies, and more.

In this guide, we explore key elements of precision medicine and their implementation into clinical practice, offering solutions and insights into the future of hematology-oncology treatments.

The Role of Genetic & Molecular Profiling in Tailoring Treatments

Genomic profiling can play a pivotal role in identifying specific genetic mutations and molecular markers associated with various hematological cancers. Through advanced techniques, such as next-generation sequencing (NGS), DNA/RNA analysis, and gene expression profiling, we can help understand the underlying drivers of a patient's disease and determine potential therapeutic targets.

For example, by using patients' molecular profiles, treatments can target the Bruton's tyrosine kinase (BTK) gene for patients with B-cell lymphoma through BTK inhibitors, a class of drugs specifically designed to inhibit the enzyme and disrupt cancer cell signaling pathways.[1] Similarly, immune checkpoint inhibitors, such as PD-L1 inhibitors, may be selected based on a patient's molecular profile to target the PD-L1 pathway, helping the immune system recognize and attack tumor cells, which is currently being explored for the treatment of acute myeloid leukemia (AML).[2]

Precision therapies are becoming increasingly important in the treatment of various cancers, including lymphoma and other hematological malignancies, where traditional treatments have often fallen short.

Additionally, certain hematological cancers can be more effectively treated using Chimeric Antigen Receptor T-cell (CAR T) therapy, by modifying a patient's T cells to target cancer cells.[3] Molecular profiling can help identify which patients are most likely to benefit from CAR T therapy based on the expression of distinct antigens.

Biomarkers & Their Applications

Biomarkers play an essential role in precision medicine by helping guide treatment decisions based on an individual's unique genetic and molecular profiles. These biomarkers can offer valuable insights into disease mechanisms, diagnosis, prognosis, predictive information, disease monitoring, and treatment responses, ultimately helping to optimize patient care in hematology-oncology (Figure 1).[4,5] They are classified into several categories, including those discussed below.



Figure 1. *Biomarkers can inform various precision medicine-based interventions across multiple categories.*

Genetic biomarkers help reveal specific mutations that can predispose individuals to certain diseases or influence their response to treatment, often serving as a prognostic measure. By recognizing these mutations via NGS or polymerase chain reaction (PCR), clinicians can tailor therapies to more effectively treat the disease and improve patient outcomes.

For example, the BCR-ABL fusion gene is a well-known genetic biomarker seen in chronic myeloid leukemia (CML).[6] The presence of this fusion gene drives the disease's pathogenesis and allows clinicians to utilize therapies such as tyrosine kinase inhibitors (TKIs) to inhibit the BCR-ABL protein, thereby controlling disease progression.[7]

Other genetic biomarkers include measurable residual disease (MRD), which are used to assess treatment response, predict relapse, and guide treatment decisions. Similarly, TP53 is a gene that creates the tumor protein, p53; patients with a TP53 mutation are more likely to experience both oncogenesis and metastasis.[8]

Molecular biomarkers include a wide range of molecules, such as DNA, RNA, protein, and metabolites, which reflect the physiological state of cells and molecular changes associated with the disease. These biomarkers can help clinicians understand the cellular environment and indicate the presence of disease or predict response to treatment. For instance, microRNAs, including miR -21 and miR-155, have been shown to play a role in the development and progression of cancers such as diffuse large B-cell lymphoma (DLBCL). [9]

Other molecular biomarkers that can be used as a predictive measure include the immunoglobulin heavy chain variable mutation in patients with leukemia, and the presence of certain mutated versions of this gene indicates poorer patient outcomes.[10] The BCR-ABL1 fusion gene is another molecular biomarker seen in patients with CML that can be targeted with TKIs to help limit the production of tyrosine kinase.

Protein-based biomarkers include proteins found in blood, tissues, or other bodily fluids that can reveal disease presence or progression. Among these are surface antigens, such as CD19, CD20, and CD22, commonly expressed on B-cells, and CD33, a marker found in AML. Similarly, high levels of beta-2 microglobulin are a predictive biomarker that can identify the presence of multiple myeloma, while levels of B-cell maturation antigens (BCMA) can predict outcomes of

multiple myeloma and other blood cancers. BCMAs and CD3 antigen may be targeted therapeutically by bispecific antibodies (BsAbs) to bring cancer cells closer in proximity to T cells and trigger T-cell activation.

Cellular biomarkers can help monitor disease status and track treatment efficacy, including circulating tumor cells (CTCs).[4] CTCs can provide real-time data on tumor burden and can be utilized to assess if treatment resistance is developing. Another important group of cellular biomarkers are MRD markers, which refer to the small number of malignant cells that may remain after treatment. For instance, mutations like NPM1 in AML can be used to detect residual malignant cells post-treatment and track disease progression and response to treatment.[11]

Immunological biomarkers can provide valuable information about the immune system's interaction with cancer cells and guide the use of immunotherapy strategies, such as PD-1/PD-L1. In Hodgkin lymphoma, PD-L1 expression on tumor cells is a predictive biomarker that can help verify patients who may benefit from immune checkpoint inhibitors,[12] such as pembrolizumab.

Research biomarkers are those utilized in a clinical trial setting, while approved and validated biomarkers are used in clinical practice as a companion diagnostic to determine which regulatory agency-approved treatment options a patient may benefit from based on the genomic alterations within their tumor.

Metabolic biomarkers, such as lactate dehydrogenase (LDH), refer to the altered molecules and pathways involved in cellular metabolism and can convey disease aggressiveness and prognosis. Elevated levels of LDH, for instance, are often linked with aggressive lymphoma and leukemia, where it serves as a marker of cellular damage or rapid tumor growth.[13]

Clinical Implementation of Precision Medicine

While precision medicine has the potential to transform patient care through innovative technologies and personalized treatment options, the clinical implementation of these can be complex. However, advanced detection technologies nonetheless play an integral role in identifying cancer at an early stage, monitoring disease progression, and assessing treatment efficacy (Table 1).

Table 1: Advanced Detection Technologies and Their Use.

Technology	Use
Liquid Biopsy	A minimally invasive technique that analyzes biomarkers from bodily fluids, such as blood, urine, or saliva, to detect and monitor cancers. It enables the detection of genetic mutations, circulating tumor DNA (ctDNA), and other molecular markers associated with cancer.
Single-Cell Sequencing	A powerful tool that examines individual cells to reveal the genetic and molecular differences between tumor cells and normal cells. This high-resolution approach can provide detailed insights into the heterogeneity of tumors.
Measurable Residual Disease Detection	The use of biomarkers to detect MRD is imperative to monitoring the effectiveness of treatment and identifying early signs of relapse, as traditional imaging or biopsy methods can often miss the low levels of residual cancer cells.

Along a similar line, it becomes important to partner with a CRO that understands and has experience working with novel treatment options, including bispecific antibodies or T-cell engagers, both of which are designed to target the genetic and molecular characteristics of a given cancer diagnosis (Figure 2).[14,15]



Figure 2. *Novel treatment options that target the genetic and molecular characteristics of a given cancer. A) Bispecific antibodies bridge cancer cells to immune cells by binding two different antigens simultaneously, effectively enhancing the immune response against the tumor by targeting multiple pathways. B) T-cell engagers are a class of immunotherapies that harness the patient immune system to better identify and eliminate cancer cells by engaging endogenous T cells and directing them to attack tumor cells.*

Precision Medicine's Impact on Patient Experience & Outcomes

Precision medicine has had a profound impact on the patient experience and outcomes in hematology-oncology. Among the benefits of this approach include:

- Enhanced efficacy and safety of these therapies
- Less aggressive impact on an elderly population, as many hematology-oncology patients are 60+ and have comorbidities, making them too frail for some of the more aggressive treatments
- Earlier detection, which allows for more timely interventions, improving overall treatment outcomes
- Improved quality of life, including longer periods of time where the patient is relatively healthy
- Minimized exposure to ineffective therapies, enhancing the overall treatment experience
- Higher response rates and longer progression free survival, reduced toxicity, and fewer side effects
- More effective management of relapsed and refractory disease

A significant initiative where precision medicine can play a considerable role due to targeted, more effective, and less toxic treatments is Project Silver, a program launched by the Oncology Center of Excellence. This initiative aims to increase the representation of older adults (i.e., 65+ years) in cancer clinical trials, addressing a critical gap in clinical research. Historically, older adults have been underrepresented in clinical trials, leading to a lack of data on how cancer treatments specifically impact this demographic. By ensuring that older patients are included in clinical research, Project Silver helps to improve the understanding of cancer therapies in this population, offering critical information into how these tailored approaches impact the unique needs of older adults.

Challenges & Solutions

While precision medicine in hematology-oncology holds great promise, its implementation faces multiple challenges that can seem daunting at first glance; however, carefully thought-out strategies can produce solutions to ensure optimal access to potentially life-saving therapies (Table 2).

Table 2: Challenges and Solutions for Hematology-Oncology Precision Medicine.

Challenges	Solutions
High Costs of Advanced Biomarker Testing NGS, liquid biopsies, and molecular profiling are crucial for identifying optimal treatments but can be expensive, especially in resource-limiting settings. The costs may limit access to valuable diagnostic tools, affecting the widespread adoption of precision medicine practices, as well as long-term disease monitoring, since many hematology-oncology patients can be in remission for many years before recurrence.	**Increased Funding & Technological Advancements** Financial investments in biomarker testing, advanced technologies, and infrastructure development are crucial to decrease costs and expand access to precision medicine approaches. Technological innovations in genomic testing may also play a role in reducing the overall cost of testing by developing more efficient sequencing platforms and cost-effective biomarker assays.
Limited Testing Availability & Site Capacities Not all treatment centers and clinical sites are equipped to manage complex genomic testing, leading to disparities in treatment access.	**Site Partnerships** Collaborating with clinical sites, such as partnerships like Worldwide's Global Site Alliance, is a potential solution to overcome testing availability and site capabilities. Through these partnerships, sites can receive education, resources, and training to help build their capacity to implement these tailored therapies.
Genomic Profile Complexities Interpreting genomic profiles is an elaborate process that requires specialized expertise. Given the variability of biomarkers across different cancers and even within the same tumor, the results can complicate treatment decisions. Therefore, clinicians must be well-versed in the latest genomic technologies and be able to differentiate between actionable mutations and those that are incidental or less relevant, which requires continuous education.	**Improved Data Analysis Tools** AI and machine learning may offer a solution to the complexity of interpreting genomic data, as these tools can help identify patterns and correlations within genomic profiles, expediting the interpretation process and enhancing clinical decision-making. AI-driven algorithms may also assist in predicting treatment response, assessing the risk of relapse, and identifying mutations more accurately.
Regulatory & Ethical Considerations Another challenge is ensuring patient privacy and the ethical use of genetic data. Genetic information is highly sensitive, and strict regulations must be in place to protect patient privacy while allowing for the use of data in clinical research.	**Strong Compliance Frameworks & Transparent Patient Communication** Addressing regulatory and ethical concerns requires establishing a strong compliance framework that guarantees patient privacy is safeguarded and the ethical use of genetic data. It's important to provide transparent communication to the patients about how their data will be used, potential risks and benefits, and the evolving nature of genomic research to cultivate trust. Moreover, staying up to date with regulatory guidelines is necessary to maintain compliance and patient confidence.
Maintaining Long-Term Monitoring With the potential for relapse in hematological cancers, long-term monitoring is essential to ensure patients continue to respond to treatment and to detect any signs of resistance or disease progression.	**Employ Consistent Monitoring Strategies** Regular biomarker monitoring, including the use of liquid biopsies or circulating tumor DNA (ctDNA), can help provide ongoing insights into a patient's disease status. These noninvasive tools ensure timely intervention and adjustments to treatment strategies as needed.

Looking Forward: Future Innovations in Targeted Therapies

As advancements in clinical research accelerate, precision medicine is at the forefront of hematology-oncology future treatment options. Below are a few key areas of focus that may increase therapy efficacy and offer new solutions for patients affected by hematological cancers.

Multi-Specific Antibodies: Tri- and tetra-specific antibodies represent the next generation of antibody-based therapies. Unlike monoclonal antibodies (mAbs) or BsAbs, multi-specific antibodies are engineered to bind to three or four different antigens simultaneously. By targeting multiple pathways at once, such as T-cell epitopes and tumor cell epitopes, these antibodies can help improve treatment efficacy and overcome some of the limitations of current treatments. These treatments can help mitigate antigen availability issues in tumors, bringing the body's own defense mechanisms into close proximity to the T-cell activation pathway.[16]

Next-Generation CAR T Therapy: Allogeneic CAR T therapy represents a promising alternative to the autologous CAR T approach, in which a patient's own T-cells are modified to target cancer cells. In allogeneic CAR T therapy, T cells are sourced from a healthy donor, making the therapy more accessible and cost-effective while addressing some of the variability and quality concerns associated with autologous therapies.[17,18]

In addition, dual or multi-targeting CAR Ts can represent multiple antigens, such as CD19, CD22, or CD20, potentially reducing relapse occurrences due to antigen escape. As a result, these therapies can improve response rates and durability, especially in ALL and certain lymphomas. These next-generation CAR T therapies are complex and often suited to younger, otherwise healthier patients.

T-Cell Receptor Therapy: T-cell receptor therapy represents another exciting development in immunotherapy and treats cancer cells with the patient's own activated T lymphocytes, which can be a more versatile treatment to target more cancer cells. However, the clinical team needs to identify and isolate the patient's own T cells that are targeting the unique tumor antigens. These can play a critical role in immune response, and by enhancing their ability to target cancer cells, this innovative treatment may offer a new avenue for cancers that are less responsive to traditional T-cell-based therapies.[19]

Gene Editing & CRISPR: Gene editing technologies, particularly CRISPR, have immense potential to revolutionize cancer treatments.[20] CRISPR enables precise editing of the genes to enhance immune function, correct gene mutations that contribute to cancer development, and even modify tumor cells to make them more susceptible to treatment. This method has the potential to significantly improve the precision and effectiveness of therapies, offering more tailored solutions for patients.

AI in Treatment Personalization: AI is likely to play a significant role in precision medicine for hematology-oncology going forward, as AI algorithms can analyze vast amounts of patient data, such as genomics and biomarkers, to help optimize treatment plans in real-time. By integrating data from various sources, AI can help identify patterns, predict response rates, and recommend treatment options, which may help improve treatment efficacy.

For example, AI can help identify more in-depth data from genomics, transcriptomics, proteomics, radiomics, digital pathological images, and other data to help support clinicians in better treating hematological cancers.[21] In addition, AI may be used to discover new biomarkers to further assist in diagnostic, prognostic, predictive, and treatment response measures to enhance patient outcomes.

Worldwide Clinical Trials

Leverage Worldwide Clinical Trial's Hematology-Oncology Expertise

At Worldwide, we understand the importance of precision medicine in advancing treatments to help improve patient outcomes in hematology-oncology. With a proven track record in advanced therapeutics such as antibody-drug conjugates (ADCs),[22] BsAbs, cutting-edge biomarkers, and more, we're committed to delivering personalized, effective treatments to the market. To learn more about how our global team can help support your drug development program and accelerate the development of innovative hematology treatments, contact us.

Last Update: 01132025

Additional Resources

- Antibody-Drug Conjugates & Bispecific Antibodies at Worldwide Clinical Trials
- Biomarkers in Oncology Studies: The Science, the Medicine, and the Impact on Development
- CRISPR, Gene-Based Therapeutics, and Clinical Trials: The Interface of Discovery and Clinical Development
- Exploring the Future of Oncology with ADCs and TILs: Key Insights From ASCO
- Immuno-Oncology: Managing Tomorrow's Responses Today: Delayed Outcomes in Dose Escalation Trials
- Addressing the Top Concerns & Unmet Needs in Oncology Clinical Research: An Award-Winning Approach

References

1. Moore DC, Thompson D. A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies. J Adv Pract Oncol. 2021 May 1;12(4):469-447. PMCID: PMC8163255. PMID: 34123480. doi: 10.6004/jadpro.2021.12.4.8.
2. Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y, Li Y. Progress of Research on PD-1/PD-L1 in Leukemia. Front Immunol. 2023 Sep 26;14:1265299. PMCID: PMC10562551. PMID: 37822924. doi: 10.3389/fimmu.2023.1265299.
3. NIH National Cancer Institute. CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers. Article. 2022. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells.
4. Confeld M, Rosu G, Dorer-Abadia C, Murphy MF. Biomarkers in Oncology Studies: The Science, the Medicine, and the Impact on Development. White Paper. Worldwide Clinical Trials Jun 2023. https://www.worldwide.com/insights/biomarker-development-in-oncology-clinical-trials/.
5. Padam S. The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans. Blog. Worldwide Clinical Trials Aug 2024. https://www.worldwide.com/blog/2024/08/oncology-biomarkers-in-hematology-treatment/.
6. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Clearly ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of Bcr-Abl Fusion in Chronic Myelogeneous Leukemia By In Situ Hybridization. Science. 1990 Oct 26;250(4980):559-562. PMID: 2237408. doi: 10.1126/science.2237408.
7. Lee H, Basso IN, Kim DDH. Target Spectrum of the BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Int Hematol. 2021 May;113(5):632-641. PMID: 33772728. doi: 10.1007/s12185-021-03126-6.
8. Tang Q, Su Z, Gu W, Rustgi AK. Mutant p53 on the Path to Metastasis. Trends Cancer. 2019 Dec 16;6(1):62-73. PMCID: PMC7485681. PMID: 31952783. doi: 10.1016/j.trecan.2019.11.004.
9. Lopez-Santillan M, Larrabeiti-Etxebarria A, Arzuaga-Mendez J, Lopez-Lopez E, Garcia-Orad A. Circulating miRNAs as Biomarkers in Diffuse Large B-Cell Lymphoma: A Systematic Review. Oncotarget. 2018 Apr 27;9(32):22850-22861. PMCID: PMC5978269. PMID: 29854319. doi: 10.18632/oncotarget.25230.
10. Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodriguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Ranj L, Baliakas P... Rosenquist R. Different Prognostic Impact of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia Depending on IGHV Gene Somatic Hypermutation Status: A Study by ERIC in HARMONY. Leukemia. 2023 Feb;37(2):339-347. PMID: 36566271. PMCID: PMC9898037. doi: 10.1038/s41375-022-01802-y.
11. Yin PY, Wang RW, Jing R, Li X, Ma JH, Li KM, Wang H. Research Progress on Molecular Biomarkers of Acute Myeloid Leukemia. Front Oncol. 2023 Feb 7:13:1078556. PMID: 36824144. PMCID: PMC9941555. doi: 10.3389/fonc.2023.1078556.
12. Meti N, Esfahni K, Johnson NA. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers (Basel). 2018 Jun 15;10(6):204. PMCID: PMC6025119. PMID: 29914088. doi: 10.3390/cancers10060204.
13. Ruan GJ, Gandhi S, Abeykoon JP, Schram S, Habermann TM, Sandefur BJ, Witzig TE. Elevated Serum Lacate in Patients with Lymphoma: It is Not Always Infection. Mayo Clin Proc Innov Qual Outcomes. 2021 Apr 8;5(2):423-430. PMCID: PMC8105511. PMID: 33997638. doi: 10.1016/j.mayocpiqo.2021.01.012.

14. FDA. Bispecific Antibodies: An Area of Research and Clinical Applications. Article. 2024. https://www.fda.gov/drugs/spotlight-cder-science/bispecific-antibodies-area-research-and-clinical-applications.

15. Rallis KS, Hillyar CRT, Sideris M, Davies JK. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). Anticancer Res. 2021 Mar;41(3):1123-1141. PMID: 33788704. doi: 10.21873/anticanres.14870.

16. Elshiaty M, Schindler H, Christopoulos P. Principles and Current Clinical Landscape of Multispecific Antibodies Against Cancer. Int J Mol Sci. 2021 May 26;22(11):5632. PMCID: PMC8198225. PMID: 34073188. doi: 10.3390/ijms22115632.

17. Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T,Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. Allogeneic CD19-Targeted CAR-T Therapy in Patients with Severe Myositis and Systemic Sclerosis. Cell. 2024 Sep 5;187(18):4890-4904.e9. PMID: 39013470. doi: 10.1016/j.cell.2024.06.027.

18. Mougiakakos D. Allogeneit CAR T Cells for Autoimmune Diseases: A Glimpse into the Future. Signal Transduct Target Ther. 2024 Oct 8;9(1):276. PMID: 39379353. PMCID: PMC11461869. doi: 10.1038/s41392-024-01998-8.

19. Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, Andersson BS. T-Cell Receptor-Based Therapy: An Innovative Therapeutic Approach for Solid Tumors. J Hematol Oncol. 2021 Jun 30;14(1):102. PMID: 34193217. PMCID: PMC8243554. doi: 10.1186/s13045-021-01115-0.

20. Confeld M, Knezevic J, Murphy MF. Clinical Development of CRISPR-Based Therapies in Oncology: Novel Therapies, Unique Challenges. White Paper. Worldwide Clinical Trials 2023. https://www.worldwide.com/insights/clinical-development-crispr-based-therapies-oncology/.

21. Liao J, Li X, Gan Y, Han S, Rong P, Wang W, Li W, Zhou L. Artificial Intelligence Assists Precision Medicine in Cancer Treatment. Front Oncol. 2023 Jan 4;12:998222. PMCID: PMC9846804. PMID: 36686757. doi: 10.3389/fonc.2022.998222.

22. Adapting to Oncology Study Needs: Flexibility in Phase I ADC Drug Development. Case Study. Worldwide Clinical Trials 2024. https://www.worldwide.com/insights/case-study-phase-i-adc-development-for-oncology-success/.